Private Market View

Jiaweida Biotechnology

Wuhan, China · Founded 2022 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
Last round

Key facts

  • Notable investors include Changzhou Hi-tech Group, Hangzhou Huafang Chuangliang Investment Management, Holley Group.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 3 names
  • ·Watchlist + deal alerts for Jiaweida Biotechnology
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Jiaweida Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Jiaweida Biotechnology

Opeartor of a biotechnology company focusing on the research and development, and production of biological raw materials. The company is positioned as a research and development, production and sales of biological raw materials and synthetic biology products.

Sector
Healthcare
HQ
Wuhan, China
Founded
2022
Ownership
Privately Held (backing)
PA Mark — not yet priced

Jiaweida Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Jiaweida Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Jiaweida Biotechnology in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.